Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 37793170.
- Also identified by DOI 10.1093/infdis/jiad433 and PMC identifier 10938212.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%-46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%-4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.
Medical subject headings
- Hepatitis C, Chronic
- Hepatitis C
- HIV Infections